HBcAg-specific CD4+CD25+regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection

Journal of Biomedical Science

Volumn 14, Issue 1, 2007, Pages 43-57

  Feng, I Che ^a   Koay, Lok Beng ^a   Sheu, Ming Jen ^a   Kuo, Hsing Tao ^a   Sun, Chi Shu ^a   Lee, Chuan ^b   Chuang, Wong Lung ^b   Liao, Shuen Kuei ^c   Wang, Shih Ling ^a   Tang, Ling Yu ^a   Cheng, Chia Ju ^a   Tsai, Sun Lung ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acute exacerbation; Chronic hepatitis B; Immune tolerance; Immunoactive; SYFPEITHI score; Tetramer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS B CORE ANTIGEN; TETRAMER; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CLONING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DISEASE EXACERBATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; TH1 CELL;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

HEPATITIS B VIRUS;

EID: 33847096821     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9129-z     Document Type: Article

References (52)

1. Chisari F.V., Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol. 156: 118-132, 2000.
2. Chisari F.V. and Ferrari C., Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13: 29-60, 1995.
3. Rehermann B. and Nascimbeni M., Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5: 215-229, 2005.
4. Beasley R.P. and Hwang L.Y., Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J. Infect. Dis. 147: 185-190, 1983.
5. Lok A.S.F., Chronic hepatitis B. N. Engl. J. Med. 346: 1682-1683, 2002.
6. Beasley R.P., Trepo C., Stevens C.E. and Szmuness W., The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol. 105: 94-98, 1977.
7. Chu C.M. and Liaw Y.F., Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection: hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 92: 220-226, 1987.
8. Tsai S.L., Chen M.H., Yeh C.T., Chu C.M., Lin A.N., Chiou F.H., Chang T.H. and Liaw Y.F., Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocyte. J. Clin. Invest. 97: 577-584, 1996.
9. Hoofnagle J.H., Shafritz D.A. and Popper H., Chronic type B hepatitis and the healthy HBsAg carrier state. Hepatology 7: 758-763, 1989.
10. Chen D.S., From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 262: 369-370, 1993.
11. Liaw Y.F. and Tsai S.L., Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection. Vir. Hep. Rev. 3: 143-154, 1997.
12. Lee W.M., Hepatitis B virus infection. N. Engl. J. Med. 337: 1733-1745, 1997.
13. Ganem D. and Prince A.M., Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350: 1118-1129, 2004.
14. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., Hwang L.H., Chang T.H. and Chen D.S., Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens: implications for hepatitis B e antigen seroconversion. J. Clin. Invest. 89: 87-96, 1992.
15. Rammensee H.G., Bachmann J., Emmerich N.N., Bachor O.A. and Stevanovic S., SYFPEITHI: database for MHC ligands and peptide motifs. Immuunogenetics 50: 213-219, 1999 (free access via: http://http://www.syfpeithi.de/).
16. Perrillo R., Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 102: 1009-1022, 2001.
17. + T cells associated with control of infection. Gastroenterology. 117: 1386-1396, 1999.
18. + cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191: 1269-1280, 2000.
19. Boni C., Penna A., Ogg G.S., Bertoletti A., Pilli M. and Cavallo C., Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963-971, 2001.
20. Lin C.L., Tsai S.L., Lee T.H., Chien R.N., Liao S.K. and Liaw Y.F., High frequency of functional anti-YMDD and mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 54: 152-161, 2005.
21. Lee T.H., Chuang Y.L., Tsai S.L. and Liaw Y.F., Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte response via peptide-MHC tetrameric complexes assay. Lett. Pept. Sci. 8: 179-185, 2002.
22. + T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment. J. Immunol. Methods 285: 71-87, 2004.
23. Ye M., Kasey S., Khurana S., Nguyen N.T., Schubert S. and Nugent C.T., MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4+T cells in healthy volunteers. Hum. Immunol. 65: 507-513, 2004.
24. Nolte-'t Hoen E.N.M., Amoroso M.G., Veenstra J., Grosfeld-Stulemeyer M.C., van Eden W. and Broeren C.P.M., Effector and regulatory T cells derived from the same T cell clone differ in MHC class II-peptide multimer binding. Eur. J. Immunol. 34: 3359-3369, 2004.
25. Reichstetter S., Ettinger R.A., Liu A.W., Gebe J.A., Nepom G.T. and Kwok W.W., Distinct T cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T cell response. J. Immunol. 165: 6994-6998, 2000.
26. Cameron T.O., Cochran J.R., Yassine-Diab B., Sékaly R.P. and Stern L.J., Detection of antigen-specific CD4+T cells by HLA-DR1 oligomers is dependent on the T cell activation state. J. Immunol. 166: 741-745, 2001.
27. high, proliferating subset. Int. Immunol. 13: 799-806, 2001.
28. Liaw Y.F., Lee C.S., Tsai S.L., Liaw B.W., Chen T.C. and Sheen I.S., T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 22: 1368-1373, 1995.
29. Tsai S.L., Chen M.H., Huang C.Y., Kuo G.C. and Liaw Y.F., Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25: 449-558, 1997.
30. Tsai S.L., Chen Y.M., Chen M.H., Huang C.Y., Sheen I.S., Yeh C.T., Huang J.S., Kuo G.C. and Liaw Y.F., Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115: 954-966, 1998.
31. Waldmann H. and Lelkovits I., Limiting dilution analysis of the cells of immune system II. The clonal basis of the immune response. Immunol. Today 5: 265-268, 1984.
32. Waldmann H. and Lelkovits I., Limiting dilution analysis of the cells of immune system II. What can be learnt?. Immunol. Today 5: 295-298, 1984.
33. Liaw Y.F., Tsai S.L., Chien R.N., Yeh C.T. and Chu C.M., Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32: 604-609, 2000.
34. Novak E.J., Liu A.W., Nepom G.T. and Kwok W.W., MHC class II tetramers identify peptide-specific human CD4+T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104: R63, 1999.
35. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C. and von Boehmer H., Inducing and expanding regulatory T cell population by foreign antigen. Nat. Immunol. 6: 1219-1227, 2005.
36. Read S. and Powrie F., CD4+ regulatory T cells. Curr. Opin. Immunol. 13: 644-649, 2001.
37. Fontenot J.D., Rasmussen J.P., Gavin M.A. and Rudensky A.Y., A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6: 1142-1151, 2005.
38. Hori S., Nomura T. and Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003.
39. MossmannT.R. and Sad S., The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17: 138-143, 1996.
40. H2 model: a personal perspective. Nat. Immunol. 7: 539-541, 2006.
41. Trinchieri G., Regulatory role of T cells producing both interferon-γ and interleukin 10 in persistent infection. J. Exp. Med. 194: F53-F57, 2001.
42. Chen W., Jin W. and Wahl S.M., Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor-β (TGF-β) production by murine CD4+ T cells. J. Exp. Med. 188: 1849-1857, 2001.
43. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry J., Coovadia H.M., Goulder P.J.R., Klenerman P., Ahmed R., and Freeman G.J., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. doi:1038/nature 05115, 2006.
44. + regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6: 1152-1159, 2005.
45. Rossol S., Marinos G., Carucci P., Singer M.V., Williams R. and Naoumov N.V., Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99: 3025-3033, 1997.
46. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J.W., Kuipers E.J., Kusters J.G. and Janssen H.L.A., Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778, 2005.
47. + regulatory T cells in patients with hepatitis B virus infection. J. Virol. 79: 3322-3328, 2005.
48. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., Zao J.M., Zhang B., Shi M., Tang Z., Fu Y.X. and Wang F.S., Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177: 739-747, 2006.
49. Milich D.R., Jones J.E., Hughes J.L., Price J., Raney A.K. and McLachlan A., Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA 87: 6599-6603, 1990.
50. Milich D.R., Jones J.E., Hughes J.L., Price J., Raney A.K. and McLachlan A., Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides. Proc. Natl. Acad. Sci. USA 88: 4348-4352, 1991.
51. Hoofnagle J.H. and Di Bisceglie A.M., The treatment of chronic viral hepatitis. N. Engl. J. Med. 336: 347-356, 1997.
52. Lok A.S.F. and McMahon B.J., Chronic hepatitis B. Hepatology 34: 1225-1241, 2001.